Publication:
Sale strategies of pharmaceutical companies in a "pharmerging" country: The problems will not improve if the gaps remain

dc.contributor.buuauthorCivaner, Murat
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentTıp Etiği Ana Bilim Dalı
dc.contributor.orcid0000-0001-5376-3499
dc.contributor.researcheridS-4188-2019
dc.contributor.scopusid24075622600
dc.date.accessioned2022-03-30T13:26:21Z
dc.date.available2022-03-30T13:26:21Z
dc.date.issued2012-08
dc.descriptionBu çalışma, Ankara Üniversitesi Sağlık Bilimleri Enstitüsünde Berna Arda'nın danışmanlığında Murat Civaner tarafından yazılan "Türkiye'de ilaç şirketlerinin kullandıkları pazarlama yöntemleri ve hekimlerin bu konudaki değerlendirmelerinin etik açıdan sorgulanması" adlı doktora tezine dayanılarak hazırlanmıştır.
dc.description.abstractObjective: This study aimed to examine the types of sales strategies used by pharmaceutical companies in a "pharmerging" market and to gain insight into the ways of avoiding the negative effects of these strategies. Method: In-depth interviews were conducted with 22 physicians and company employees in the six largest cities of Turkey. The interviews were analyzed using content analysis. Results: Various sales strategies, both legal and illegal, are universally applied. These methods target prescribers, patients, pharmacists, and society in general. Different types of companies, organizations, professionals, and science and ethical principles are used as means. Companies intervene immediately to prevent developments that may decrease sales, and exploit the educational and infrastructural needs. In contrast, physicians are overconfident about the effects of marketing and insufficiently educated on how to cope with the strategies and the drugs on the market, which make them vulnerable. Under these conditions, along with worldwide competition and economic volatility, policies that aim to set frameworks for pharmaceutical relationships have failed. Conclusion: Interventions are crucial, including instituting a national drug policy, minimizing the exposure to marketing, and addressing the educational and infrastructural needs of the prescribers. Without these interventions, gaps will continue to be exploited by companies for their own advantage, and the problems related to marketing will persist.
dc.identifier.citationCivaner, M. (2012). "Sale strategies of pharmaceutical companies in a "pharmerging" country: The problems will not improve if the gaps remain". Health Policy, 106(3), 225-232.
dc.identifier.endpage232
dc.identifier.issn0168-8510
dc.identifier.issn1872-6054
dc.identifier.issue3
dc.identifier.pubmed22682762
dc.identifier.scopus2-s2.0-84863780162
dc.identifier.startpage225
dc.identifier.urihttps://doi.org/10.1016/j.healthpol.2012.05.006
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0168851012001509
dc.identifier.urihttp://hdl.handle.net/11452/25460
dc.identifier.volume106
dc.identifier.wos000306885900002
dc.indexed.scopusScopus
dc.indexed.wosSCIE
dc.indexed.wosSSCI
dc.language.isoen
dc.publisherElsevier Ireland
dc.relation.journalHealth Policy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHealth care sciences & services
dc.subjectMarketing
dc.subjectDrug industry
dc.subjectPhysicians
dc.subjectMedical ethics
dc.subjectProfessionalism
dc.subjectDrug companies
dc.subjectMedical journals
dc.subjectIndustry
dc.subjectDoctors
dc.subjectPhysicians
dc.subjectSponsorship
dc.subjectAssociation
dc.subjectGuidelines
dc.subjectEducation
dc.subjectAuthors
dc.subject.emtreeArticle
dc.subject.emtreeDrug industry
dc.subject.emtreeDrug marketing
dc.subject.emtreeEmployee
dc.subject.emtreeHealth care policy
dc.subject.emtreeHealth economics
dc.subject.emtreeInterview
dc.subject.emtreePharmacist
dc.subject.emtreePhysician
dc.subject.emtreeQualitative research
dc.subject.meshDrug industry
dc.subject.meshEthics, medical
dc.subject.meshHumans
dc.subject.meshMarketing
dc.subject.meshQualitative research
dc.subject.meshTurkey
dc.subject.scopusConflict of Interests; Honorarium; Consulting Fees
dc.subject.wosHealth care sciences & services
dc.subject.wosHealth policy & services
dc.titleSale strategies of pharmaceutical companies in a "pharmerging" country: The problems will not improve if the gaps remain
dc.typeArticle
dc.wos.quartileQ2 (Health policy & services)
dc.wos.quartileQ3 (Health care sciences & services)
dc.wos.quartileQ2
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Tıp Etiği Ana Bilim Dalı
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: